PRMT5 and Miyoshi myopathy: We then analysed the MTAP status and MTA intracellular content in a panel of MM and normal mesothelial cell lines and, in line with what previously reported for other cancer types,24, 25 we found a higher MTA content in MTAP‐deleted MM cells and a greater cytotoxic effect of exogenous addition of MTA, the natural inhibitor of PRMT5, in these cells.